483 results about "Cellular functions" patented technology

Provided are multi-wavelength phototherapy devices, systems and methods for the treatment of a disorder or disease, including multi-wavelength low level light therapy (“PBM”), in particular to multi-wavelength PBM and other phototherapy systems and methods for improving functionality in and / or restoring functionality to a cell and / or tissue through the coordinated and targeted delivery to the cell or tissue of two or more doses of light having distinct wavelengths, wherein the two or more doses of light, when delivered in a coordinated fashion, can stimulate the activity of two or more light sensitive factors that, when activated, provide and / or enhance a desired target cell functionality. Ophthalmic phototherapy devices, systems, and treatment methods to expose an eye to selected multi-wavelengths of light to promote the healing of damaged or diseased eye tissue. The devices include a housing having an interior; an eyepiece disposed on the housing and configured and arranged for placement of an eye of the patient adjacent the eyepiece; a first light source producing a first light beam having a first therapeutic wavelength and disposed within the housing; a second light source producing a second light beam having a second therapeutic wavelength and disposed within the housing, where the second therapeutic wavelength differs from the first therapeutic wavelength by at least 25 nm.

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention discloses a multi-omics analysis method and device, electronic equipment and a storage medium, and relates to the technical field of biological information, and the method comprises the following steps: obtaining a spatial single cell function map set based on multi-omics data, the multiple omics data at least comprise single cell transcriptome data, spatial transcriptome data, single cell chromatin transposase accessibility sequencing ATAC data and whole genome association research GWAS data, and the spatial single cell function map set comprises a plurality of maps used for indicating spatial distribution of different omics data; and establishing a mapping relationship from the spatial transcriptome data to the single cell transcriptome data, wherein the mapping relationship indicates spatial position information of each cell in the single cell transcriptome data. By utilizing the method, the flexibility during multi-omics analysis is improved, and the data integration capability is improved.

Aspects described herein pertain to engineered chimeric antigen receptors (CARs) and compositions thereof having specificity and affinity for fluorescein containing ligands presented on the surface of tumor cells. Also provided herein are compositions including CARs further comprising a spacer arm and methods of making and using these compositions.

The invention provides a method for enhancing Treg cell functions and application, and belongs to the technical field of cell engineering. According to the method, hUC-MSCs are irradiated by gamma rays to form feeder layer cells, and then the feeder layer cells and Treg cells are co-cultured to obtain the Treg cells with enhanced cell functions. Through the co-culture of the feeder layer cells and the Treg cells, the inhibition ability of the Treg cells on activation and proliferation of immune cells can be enhanced, and the feeder layer cells and the Treg cells can be used as universal cells in clinical researches of autoimmune diseases, graft versus host diseases and the like.

The invention belongs to the technical field of molecular biology, and particularly relates to an anti-CD28 nano antibody as well as a preparation method and application thereof. The preparation process of the anti-CD28 nano antibody provided by the invention comprises the following steps: constructing a CD28 antigen to immunize alpaca, performing phage library construction on the immunized alpaca PBMC, screening the phage library, and selecting a correct sequence to construct, express and purify; and finally obtaining the anti-CD28 nano antibody through cell function detection and screening. The nano antibody provided by the invention has specific recognition and binding capacity to CD28, and has the advantages of strong specificity, high sensitivity and the like; meanwhile, the development and production cost of the CD28 antibody is effectively reduced, and the antibody expression time is shortened.

The present invention relates to the field of stem cell technology. The present invention discloses a method for inducing stem cells to secrete specific factors, which includes stimulating stem cells with high-frequency waves, emitting sound waves of a specific frequency to stem cells, regulating stem cells in a hypoxic environment, culturing stem cells in a hypoxic environment, stimulating stem cells with oxidative stress, and subjecting stem cells to oxidative stimulation treatment. The present invention can significantly enhance the proliferation ability of stem cells, promote the secretion of multiple active factors, and improve cell function and adaptability. As a non-invasive physical method, high-frequency wave stimulation can activate internal cell signal pathways without introducing exogenous substances, significantly improving the proliferation ability and tissue repair potential of stem cells. Hypoxic environment regulation simulates the naturally existing microenvironmental conditions in the body, greatly promoting the secretion of active factors such as vascular endothelial growth factor, basic fibroblast growth factor, and brain-derived neurotrophic factor for tissue repair and immune regulation.

The invention belongs to the field of gene engineering. Specifically, the invention relates to a base editing system for optimizing engineered T cells and application of the base editing system. The present invention provides a base editing system for modifying engineered T cells, comprising: i) a base editing polypeptide, and / or an expression construct encoding a base editing polypeptide, the base editing polypeptide comprising a DNA binding protein and at least one deaminase domain; ii) a guide RNA, and / or an expression construct encoding a guide RNA, the guide RNA targeting any one of TRAC, TGFBR2, PD-1, CISH, and / or FAS genomic regions, or any combination thereof. The base editing system disclosed by the invention has high efficiency of a gene editing tool and low Indel frequency, can realize accurate editing of T cell function enhancement related genes, and has important value for expanding application scenes of a base editing technology in the fields of preparation of safe and efficient engineered T cells and the like.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to application of bifidobacterium longum subsp. Infantis Y46 in the anti-aging aspect. The bifidobacterium longum subsp. Infantis Y46 is obtained from excrement of infants. Animal experiments prove that living cell thalli (Y46) and thermally inactivated cell thalli (HKY46) obtained by culturing the bifidobacterium longum subsp. Infantis Y46 by using an MRS liquid culture medium containing L-cysteine hydrochloride (0.05%, v / v) can significantly reduce accumulation of lipofuscin in a host, and prolong the healthy life and life of the host. Therefore, the bifidobacterium longum subsp. Infantis Y46 is a promising probiotic and a promising metagen with an anti-aging function.

The invention discloses an experimental method based on depletion-type nk cells as a lung cancer treatment target, and relates to the technical field of bioinformatics. Comprising the following steps: S1, data processing; s2, identification of cell subset characteristic genes and cell type annotation; s3, re-clustering the NK cells; s4, NK cell function annotation; s5, differential gene expression analysis; s6, analyzing the difference of activation and inhibition of receptor expression by the RGS1 + NK cells through single cells; s7, performing quasi-time sequence analysis; s8, carrying out cell culture and siRNA transfection; s9, detecting the expression condition of an NK92mi cell activated receptor after the RGS1 is knocked down; s10, carrying out a lactic dehydrogenase release experiment; s11, measuring the IFN-gamma content of the cell supernatant; and S12, virtual screening of drugs. Through analysis and experimental verification, the key function of RGS1 in NK cell depletion in lung cancer is disclosed, and a new and potential molecular target is provided for lung cancer treatment.

The invention belongs to the technical field of molecular biology, and particularly relates to an anti-CD28 nano antibody as well as a preparation method and application thereof. The preparation process of the anti-CD28 nano antibody provided by the invention comprises the following steps: constructing a CD28 antigen to immunize alpaca, performing phage library construction on the immunized alpaca PBMC, screening the phage library, and selecting a correct sequence to construct, express and purify; and finally obtaining the anti-CD28 nano antibody through cell function detection and screening. The nano antibody provided by the invention has specific recognition and binding capacity to CD28, and has the advantages of strong specificity, high sensitivity and the like; meanwhile, the development and production cost of the CD28 antibody is effectively reduced, and the antibody expression time is shortened.

The invention relates to a preparation method of a 3D printing high-density cell tubular vascular graft. The preparation method comprises the following steps: sucking a supernatant obtained by centrifuging a cell suspension away and only remaining bottom pure cells; the preparation method comprises the following steps: uniformly stirring and mixing OMA, pig gelatin and an LAP photoinitiator in a Hank's solution to form a hydrogel precursor solution; extruding the pure cells and the hydrogel precursor solution from a three-axis nozzle by using printing equipment, and immersing the pure cells and the hydrogel precursor solution into a calcium chloride solution; lyase is added to degrade the hydrogel precursor solution, the hydrogel precursor solution is completely degraded, and an independent single-layer pipeline structure with only a remaining pure cell layer is obtained. The invention provides a method for manufacturing high-density pure-cell lumen constructs to mimic native blood vessels by using a self-made microfluidic coaxial 3D bioprinting device. And after the support hydrogel on the inner layer and the outer layer is removed, a single-layer tubular structure of high-density MOVAs only limited to pure cells is obtained. The cells in the pure cell vascular constructs exhibit good cell viability and cell function.

The invention relates to the technical field of biomedicine, in particular to a fusion protein combining a double-target chimeric antigen receptor with PD-1 and IL-21, and an extracellular domain of the double-target chimeric antigen receptor sequentially comprises any one of the following components from an N terminal to a C terminal: CIgG scFv-MSLN scFv, CIgG scFv-CLDN18.2 scFv, CIgG scFv-MSLN scFv and CIgG scFv-CLDN18.2 scFv; wherein '-' is a connecting peptide; the cell further comprises a hinge region, a transmembrane region and an intracellular signal transduction region; pD-1 scFv and IL-21 are further fused at the N end of the intracellular signal transduction region. According to the invention, two chimeric antigen receptors of double-target combined PD-1 and IL21 fusion proteins are constructed, and through a synergistic anti-tumor strategy, CAR-T cell functions are enhanced, tumor microenvironment (TME) inhibition is overcome, T cell durability is improved, and synergy is realized.

Provided are chimeric AP-1 transcription factor polypeptides. In some aspects, provided are chimeric polypeptides comprising an N-terminal domain of a first AP-1 transcription factor and a bZIP domain of a second AP-1 transcription factor. Such polypeptides may further comprise a C-terminal domain of an AP-1 transcription factor. In other aspects, provided are chimeric polypeptides comprising a bZIP domain of a first AP-1 transcription factor and a C-terminal domain of a second AP-1 transcription factor. Such polypeptides may further comprise an N-terminal domain of an AP-1 transcription factor. In some instances, T cells expressing the chimeric AP-1 transcription factor polypeptides exhibit enhanced T cell function relative to T cells expressing only native wild-type AP-1 transcription factors. Also provided are T cells expressing the chimeric polypeptides and methods of using such cells to treat a condition (e.g., cancer, infection, and / or the like) in a subject in need thereof.

Disclosed are systems and methods for detecting extracellular ligands and / or inducing expression of an exogenous or endogenous gene. The disclosed systems and methods typically include and / or utilize (i) first and second exogenous extracellular sensors, and third and fourth exogenous extracellular sensors; and (ii) an expression vector comprising a target gene operably linked to a hybrid promoter sequence. The hybrid promoter sequence of the expression vector includes a minimal promoter for inducing transcription and the hybrid promoter sequence further includes interspaced transcription regulator binding sites upstream of the minimal promoter that bind two or more transcription regulators of the extracellular sensors that are released from the extracellular sensors when the extracellular sensor bind an extracellular ligand.

The invention belongs to the technical field of medical instruments, and discloses a digestive endoscopy diseased region accurate positioning and marking device which comprises a controller, an endoscope hose is fixedly connected to the bottom of the controller, and an instrument insertion opening is formed in the right side of the controller. Through the arrangement of the sleeve, the dye tube, the pressurization air bag and the baffle, after an operator observes a diseased region through the endoscope hose, the operator only needs to align the endoscope hose to the diseased region, and by pressing the pressurization air bag, air in the pressurization air bag enters the dye tube through the inner hose; the baffle can be pushed to rotate outwards under the action of air pressure, meanwhile, methylene blue in the dye tube is sprayed out under the action of air flow, a diseased region is marked, the methylene blue can be absorbed by normal mucous membrane cells, and diseased tissue shows dyeing difference due to abnormal cell function and poor absorption capacity, so that the diseased region is marked. Therefore, the effect of accurate positioning is achieved.

The invention relates to a natural plant functional component based on cell function regulation, a natural plant composition and application thereof. The natural plant composition is prepared from the following raw material components in parts by weight: 1000 to 1600 parts of phospholipid, 200 to 400 parts of cholesterol, 200 to 400 parts of prinsepia utilis royle oil, 100 to 300 parts of ergothioneine and 200 to 500 parts of nicotinamide mononucleotide. Compared with the prior art, the composition not only can cover multi-target composite components with ROS removal, mitochondrial autophagy activation and NAD + level improvement, but also can improve the component permeability by optimizing the delivery technology, thereby effectively improving the skin anti-aging effect and the like.

This disclosure provides modified natural killer (NK) cells possessing both NK cell function and dendritic cell function and method of culturing the same. By administration of the modified NK cell, cancer cells in a subject may be effectively inhibited via cell-mediated immunity.

The invention belongs to the technical field of cancer drugs, and particularly relates to a pancreatin-responsive bioactive peptide, nanofiber hydrogel prepared from the pancreatin-responsive bioactive peptide and application of the pancreatin-responsive bioactive peptide. The trypsin response-based bioactive peptide 1-Pept (the sequence of the trypsin response-based bioactive peptide 1-Pept is naphthylacetic acid-phenylalanine-glycine-tyrosine-lysine-cysteine-aspartic acid) and an anti-cancer drug adriamycin can be jointly assembled into 1-Pept / Dox nanofiber hydrogel, and a cytoskeleton can be destroyed by combining nanofibers with Dox; a series of cascade events resulting in cellular dysfunction are initiated, including mitochondrial damage, activation of apoptosis-associated proteins, and nuclear damage, thereby cooperatively causing tumor ablation. Compared with the existing single anti-cancer drug adriamycin, the in-vivo and in-vitro anti-cancer effect of the compound is obviously superior to that of the adriamycin pure drug, and the compound has obvious advantages in the aspect of resisting colon cancer.

In general, the current disclosure relates to pre-queuosine1 (preQ1) affecting mammalian cellular function, including affecting proliferation of the mammalian cell. Aspects herein further show that preQ1 can affect tRNA abundance.

The invention belongs to the technical field of cell biology, and particularly relates to a preparation method of tumor enhanced targeting and therapeutic function extracellular vesicles and a chip device. The invention firstly provides an integrated chip device which is provided with a cell screening module and a functional preparation module and comprises a plurality of functional layers, wherein one functional layer is provided with a cell evolution screening area with gradient for cell screening, and the other functional layer is provided with a cell electric remodeling area for cell functionalization transformation. The invention innovatively proposes that tumor cells with strong metastasis ability are screened based on culture gradient, the tumor cells with stronger invasion ability are distinguished by utilizing spatial segmentation, then the screened cell subpopulation is transferred to a cell electric remodeling area in combination with overturning operation of the chip, and the cell subpopulation is transferred to the cell electric remodeling area in a manner of focusing an electric field through nanopores. And meanwhile, therapeutic molecules are efficiently delivered to realize cell transformation, so that the transformed cells can enhance the output of extracellular vesicles with a therapeutic function.

The present disclosure provides gene editing methods for modulating the expression of an inhibitor of DNA-binding E-protein transcription factors, namely Id3, and thereby affecting T cell function. First, it provides experimental evidence that Id3 is critical to the persistence and function of tissue-infiltrating GVHD T cells in a mouse model. Id3 reduces chromatin accessibility (ChrAcc) of transcription factors (TFs) that drive T cell PD-1 transcription, differentiation and dysfunction. Id3 loss increases PD-1 expression and impairs tissue-infiltrating Th1 cells. Second, it provides proof-of-concept that targeting ID3 in human T cells using a CRIPSR / Cas9 knockout (KO) prevents xeno-GVHD but preserves the anti-leukemic activity of chimeric antigen receptor (CAR)-T cells. Third, it provides experimental evidence that ectopic expression of Id3 in engineered human CAR-T cells enhances the ability of these cells to eliminate tumors.

The present disclosure relates to Machado-Joseph disease (MJD), or spinocerebellar ataxia type 3 (SCA3), an autosomal dominantly inherited neurodegenerative disorder that is caused by an over-repetition of the polyglutamine-codifying region in the ataxin-3 (ATX7V3) gene. Expanded ATXN3 is prone to aggregate and disturbs diverse cellular systems, ultimately leading to cell dysfunction and death in specific neuronal populations. To date, no treatment able to reverse or stall MJD / SCA3 progression has been developed. Strategies based on the suppression of the deleterious gene products have demonstrated promising results in pre-clinical studies. Nonetheless, these strategies do not target the root cause of the disease, producing an incomplete and / or transient therapeutic effect in target cells or tissues. Recently, gene-based therapeutics, including the bacterial clustered regularly interspaced short palindromic repeat (CRISPR) systems for gene edition, have been successfully used to permanently inactivate and correct disease-related genes, holding promise for the development of a definitive cure for inherited diseases.

The invention discloses a drug system for regulating and controlling oxidation reduction in immune cells through ion delivery as well as a preparation method and application of the drug system. The drug system comprises polymer vesicles on the inner layer and liposome vesicles on the outer layer, the polymer vesicles are formed by self-assembly of diblock polymers PEI-b-PLA or PEI-b-PLA, and the surfaces of the polymer vesicles are modified by antibodies targeting MDSC cell surface markers. The outer wall of the polymer vesicle is positively charged and is compounded with a therapeutic gene with a cell redox regulation function through electrostatic interaction, and an iron ion therapeutic drug capable of realizing cell redox regulation is loaded in the polymer vesicle; the liposomal vesicles are modified with a targeted disintegrating enzyme substrate polypeptide-PEG. According to the medicine system, regulation and control of MDSC in the placenta and regulation and control of immunity in the placenta can be achieved, influences on functions of other cells in the placenta are avoided, the situation that medicine leaks through a maternal-fetal barrier can be effectively reduced, toxicity to a fetus and a maternal body is reduced, and a new thought is provided for effective immunotherapy of placenta dysfunction diseases.

The invention discloses a medium-auricular-biliary-neoplasm organoid culture medium and a construction method of a medium-auricular-biliary-neoplasm organoid, and relates to the technical field of organoid models. By optimizing the formula of the culture medium, the survival rate, the proliferation rate and the controllability of the differentiation direction of the middle auricular and biliary neoplasm cells are remarkably improved, the organoid forming time is short, the modeling success rate is high, and stable passage amplification can be achieved. Compared with an existing in-vivo and in-vitro model, the middle ear and bile adipoma organ can truly reproduce the three-dimensional structure and the cell function of middle ear and bile adipoma. The organ with the middle ear and gallbladder neoplasm provides a more reliable and innovative platform for accurately simulating the tissue microenvironment of the middle ear and gallbladder neoplasm, can lay a foundation for subsequent gene editing and drug screening research, and is beneficial to deep exploration of the generation mechanism and treatment method of the middle ear and gallbladder neoplasm.

The present disclosure provides gene editing methods for modulating the expression of an inhibitor of DNA-binding E-protein transcription factors, namely Id3, and thereby affecting T cell function. First, it provides experimental evidence that Id3 is critical to the persistence and function of tissue-infiltrating GVHD T cells in a mouse model. Id3 reduces chromatin accessibility (ChrAcc) of transcription factors (TFs) that drive T cell PD-1 transcription, differentiation and dysfunction. Id3 loss increases PD-1 expression and impairs tissue-infiltrating Th1 cells. Second, it provides proof-of-concept that targeting ID3 in human T cells using a CRIPSR / Cas9 knockout (KO) prevents xeno-GVHD but preserves the anti-leukemic activity of chimeric antigen receptor (CAR)-T cells. Third, it provides experimental evidence that ectopic expression of Id3 in engineered human CAR-T cells enhances the ability of these cells to eliminate tumors.

The invention relates to the field and discloses application of terahertz waves or intermediate infrared in preparation of adoptive T lymphocytes. The Terahertz wave or mid-infrared modulation technology is utilized to specifically regulate and control the functions of the T cells in a flowing irradiation mode, and the functions of the T cells from different sources are enhanced under the conditions that no medicine is used and no exogenous gene is introduced. Terahertz wave or mid-infrared stimulation is applied to the T cells in a flowing irradiation mode, specific terahertz wave or mid-infrared frequency for remarkably enhancing the functions of the T cells is determined in a frequency screening mode, and after the optimal irradiation frequency is determined, the T cells with the most remarkable function improvement are further input back into a donor. The T cells stimulated by terahertz waves or mid-infrared rays can play a powerful immune function in a tumor microenvironment so as to inhibit further development of tumors.

The invention relates to application of a fish maw and colla corii asini composition in preparation of anti-aging products, and belongs to the technical field of health-care products. The mass ratio of the fish maw to the colla corii asini in the fish maw and colla corii asini composition is (1-2): 1, and the colla corii asini is Dongshan colla corii asini powder. The fish maw and colla corii asini composition has the advantages that the anti-oxidation level, the collagen metabolism level and the cell function level are mutually cooperated, the anti-oxidation capability is obviously improved, the dermis layer is delayed to be thinned, the skin elasticity is effectively improved, and the anti-aging effect is achieved.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, that bind to or target multiple genes or regulatory elements thereof, for instance in a T cell. In some aspects, the provided epigenetic-modifying DNA-targeting systems promote increased transcription of one or more first genes and promote repressed transcription of one or more second genes. In some aspects, the provided epigenetic-modifying DNA-targeting systems modulate a T cell function, such as a T cell phenotype or activity. Also provided herein are polynucleotides, vectors, cells, methods, and uses related to the provided epigenetic-modifying DNA-targeting systems, for example in modulating T cells, such as in connection with methods of adoptive T cell therapy.

The invention relates to the field of biomedical materials, in particular to an Nb2C MXene composite functional film capable of promoting angiogenesis and a preparation method of the Nb2C MXene composite functional film, the Nb2C MXene composite functional film is particularly suitable for diabetes wound healing, and the Nb2C MXene composite functional film comprises an Nb2C MXene functionalized collagen vitrified film layer, and a carboxymethyl chitosan vitrification film layer, wherein a nano interlocking interface is formed between the Nb2C MXene functionalized collagen vitrified membrane layer and the carboxymethyl chitosan vitrified membrane layer; the Nb2C MXene functionalized collagen vitrified membrane layer is hydrophobic, the carboxymethyl chitosan vitrified membrane layer is hydrophilic, through the double-layer asymmetric structural design, the inner layer is tightly attached to a wound, the outer layer prevents adhesion of bacteria and tissues, and the barrier function in the wound healing process is effectively guaranteed; the adopted Nb2CMXene has excellent ROS (reactive oxygen species) removal capacity, oxidative stress of wound parts can be effectively relieved, cell damage is avoided, and cell functions are recovered.